A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin Plus 5-Fluorouracil Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck.
Latest Information Update: 30 Aug 2021
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary) ; Cisplatin; Fluorouracil
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- 20 Aug 2021 Results evaluating clinical and laboratory prognostic factors in patients enrolled in the practice - changing TPF arm and report the long-term update of the TAX 323 study published in the European Journal of Cancer
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 13 May 2014 New source identified and integrated (German Clinical Trials Register; DRKS00005527).